Dihydromyricetin protects against Doxorubicin-induced cardiotoxicity through activation of AMPK/mTOR pathway
- PMID: 35278898
- DOI: 10.1016/j.phymed.2022.154027
Dihydromyricetin protects against Doxorubicin-induced cardiotoxicity through activation of AMPK/mTOR pathway
Abstract
Background: Doxorubicin (DOX) is a highly effective broad-spectrum antitumor agent, but its clinical administration is limited by self-induced cardiotoxicity. Dihydromyricetin (DHM) is a flavonoid compound extracted from the Japanese raisin tree. Evidence that DHM has neovascular protective properties makes it a candidate for studying cardiotoxicity prevention strategy. However, it remains unknown if DHM can protect against cardiotoxicity caused by DOX.
Purpose: The present study was performed to evaluate the protective effect of DHM on DOX-induced cardiotoxicity in vivo and in vitro.
Methods: C57BL/6 mice were intraperitoneally injected with DOX to construct cardiac injury model in vivo, and AC16 cells were exposed to DOX to induce cell injury in vitro. Left ventricular function of mice were detected by echocardiography, the apoptosis of mice cardiac tissue and AC16 cells were detected by TUNEL and Hoechst33342/PI double staining. The expression of apoptosis and autophagy related proteins were detected by western blotting, immunohistochemical staining and immunofluorescence staining.
Results: Echocardiographic results showed that DOX-induced cardiotoxicity were significantly alleviated by DHM pretreatment. DOX induced cardiotoxicity of mice by inhibiting AMPK activation, increasing apoptosis and decreasing autophagy. However, under the same conditions, the heart tissue of DHM-pretreated mice showed increased autophagy and decreased apoptosis via activation AMPK/mTOR pathway. The same results were observed in vitro, and it was also found that DHM can inhibit the production of intracellular ROS in vitro.
Conclusion: DHM protects against cardiotoxicity by inhibiting apoptosis and oxidative stress and it can allevate theautophagy inhibition caused by DOX through AMPK/mTOR pathway. DHM preconditioning may be a breakthrough in protecting DOX-induced cardiotoxicity in the future clinical applications.
Keywords: AMPK; Autophagy; Cardiotoxicity; Dihydromyricetin; Doxorubicin.
Copyright © 2022 Elsevier GmbH. All rights reserved.
Similar articles
-
Dihydromyricetin alleviates doxorubicin-induced cardiotoxicity by inhibiting NLRP3 inflammasome through activation of SIRT1.Biochem Pharmacol. 2020 May;175:113888. doi: 10.1016/j.bcp.2020.113888. Epub 2020 Feb 27. Biochem Pharmacol. 2020. PMID: 32112883
-
Enhanced-autophagy by exenatide mitigates doxorubicin-induced cardiotoxicity.Int J Cardiol. 2017 Apr 1;232:40-47. doi: 10.1016/j.ijcard.2017.01.123. Epub 2017 Jan 27. Int J Cardiol. 2017. PMID: 28159361
-
Resolvin E1 protects against doxorubicin-induced cardiotoxicity by inhibiting oxidative stress, autophagy and apoptosis by targeting AKT/mTOR signaling.Biochem Pharmacol. 2020 Oct;180:114188. doi: 10.1016/j.bcp.2020.114188. Epub 2020 Aug 1. Biochem Pharmacol. 2020. PMID: 32750329
-
[Dihydromyricin alleviates doxorubicin-induced myocardial injury by inhibiting NLRP3 inflammasome in rats].Zhonghua Bing Li Xue Za Zhi. 2020 Oct 8;49(10):1046-1051. doi: 10.3760/cma.j.cn112151-20200108-00020. Zhonghua Bing Li Xue Za Zhi. 2020. PMID: 32992421 Chinese.
-
A novel compound DT-010 protects against doxorubicin-induced cardiotoxicity in zebrafish and H9c2 cells by inhibiting reactive oxygen species-mediated apoptotic and autophagic pathways.Eur J Pharmacol. 2018 Feb 5;820:86-96. doi: 10.1016/j.ejphar.2017.12.021. Epub 2017 Dec 9. Eur J Pharmacol. 2018. PMID: 29229534
Cited by
-
Anthracycline Therapy Modifies Immune Checkpoint Signaling in the Heart.Int J Mol Sci. 2023 Mar 23;24(7):6052. doi: 10.3390/ijms24076052. Int J Mol Sci. 2023. PMID: 37047026 Free PMC article.
-
Emerging role and therapeutic implication of mTOR signalling in intervertebral disc degeneration.Cell Prolif. 2023 Jan;56(1):e13338. doi: 10.1111/cpr.13338. Epub 2022 Oct 3. Cell Prolif. 2023. PMID: 36193577 Free PMC article. Review.
-
Strategic developments in the drug delivery of natural product dihydromyricetin: applications, prospects, and challenges.Drug Deliv. 2022 Dec;29(1):3052-3070. doi: 10.1080/10717544.2022.2125601. Drug Deliv. 2022. PMID: 36146939 Free PMC article. Review.
-
Dietary Supplements and Natural Products: An Update on Their Clinical Effectiveness and Molecular Mechanisms of Action During Accelerated Biological Aging.Front Genet. 2022 Apr 28;13:880421. doi: 10.3389/fgene.2022.880421. eCollection 2022. Front Genet. 2022. PMID: 35571015 Free PMC article. Review.
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous
